RAPISCAN

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug RAPISCAN contains one active pharmaceutical ingredient (API):

1	Regadenoson UNII 2XLN4Y044H - REGADENOSON
	Regadenoson is a low affinity agonist (Ki ≈ 1.3 μM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki >16.5 μM), and very low, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow (CBF).
	Read more about Regadenoson

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RAPISCAN Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EB21		C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations
Discover more medicines within C01EB21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1493939
ES	Centro de información online de medicamentos de la AEMPS	110643001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	506963
FR	Base de données publique des médicaments	69075222
GB	Medicines & Healthcare Products Regulatory Agency	194865
HK	Department of Health Drug Office	66576
IT	Agenzia del Farmaco	042729018
LT	Valstybinė vaistų kontrolės tarnyba	1056396
PL	Rejestru Produktów Leczniczych	100315321
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64487001